Advertisment
By Rayhan Beebeejaun
The Directed Acyclic Graph (DAG) is a new structure of Distributed Ledger Technology (DLT) which has been marketed recently as Blockchain...
There’s something almost magical about the world of partnerships.Rather than considering everyone around you a threat, you change your perspective entirely, forget the...
Internet fitness company Keep Inc. raised the single largest fundraising round in the world’s Internet fitness industry, with Goldman Sachs leading the $127...
Efficient Neural Audio SynthesisAuthors: Nal Kalchbrenner, Erich Elsen, Karen Simonyan, Seb Nouri, Norman Casagrande, Edward Lockhart, Sander Dieleman, Aaron van den Oord, Koray...
In terms of top performers, last year was a pretty great year for Australian IPOs. At time of writing there are five companies that listed in 2017 that are more than 500% up on their listing price. The companies provide a good insight into the current zeitgeist of the Australian micro-cap sector. There are two infant formula companies, one exploratory mining company, one medicinal cannabis company and one 3D printing company.
Company
Listing price
Current price
Return
Wattle Health
$ 0.20
$ 2.26
1030%
Cann Group
$ 0.30
$ 2.75
817%
Bubs
$ 0.10
$ 0.72
620%
Titomic
$ 0.20
$ 1.22
510%
Cobalt blue
$ 0.20
$ 1.40
600%
While initially you might think trying to find common ground between such a diverse set of companies would be difficult, there is one thing that all these companies share; low or nearly non-existent receipts from customers. The five companies listed above have a combined market capitalisation of 960 million, yet their combined receipts for the first six months of FY18 is only 2.8 million.That’s an annualised price to revenue ratio of 172, a ridiculous metric by any stretch of the imagination.
To be clear, each company has their own, potentially legitimate reason why revenue is currently low or non-existent. Cobalt Blue is still in the exploratory stages of assessing mining sites, Titomic is in the process of setting up its operations centre in Melbourne, CannGroup has multiple regulatory and legislative hurdles to pass before it can start selling cannabis andBubs and Wattle Health are both waiting on their CFDA licenses that will allow them to sell their products in China.
A cynical explanation for this coincidence is that it is much harder to disappoint shareholders when you are pre-revenue. A pre-revenue company is all possibility: When you are pre-revenue there are no pesky questions about profitability, client retention, or growth rates. No pre-revenue company was ever caught giving misleading statements about new customers or cooking up elaborate scheme
s to artificially inflate their quarterly cash flows. A company that is already making money usually needs actual growth to cause an increase in share price, all a pre-revenue company has to do is make vague claims about massive potential market sizes.
While the initial returns may be spectacular, history suggests the ASX can tire pretty quickly of these sorts of companies. You only need to look back at the best performing IPO’s from 2016 to confirm this. Interestingly enough, there are six IPO’s from 2016 that have at some point traded at over 500% return, but as of today only Afterpay Touch is still trading above this benchmark. Get Swift’s problems have been well publicised, but there are others whose drop in value have been nearly as dramatic.
Aurora Labs, a 3D printing company at one point reached a high of $3.93 before additional capital raises and elusive revenue growth pushed the share price down to it’s current $0.55. Creso Pharmaceutical, another cannabis related company (whoever said the ASX is too predictable) has dropped from its high of $1.36 to $0.70
Even without the benefit of history it seems at least some of the 2017 IPO's are pretty overvalued currently. To take Wattle Health as an example, the current market capitalisation is around $210 million vs current sales of $329,000 a month. If Wattle Health was a mature company with normal growth prospects you would expect it to be trading at around 10X gross profit (keep in mind this does not include administrative, marketing or interest costs), which would require sales of $3,017,248 a month at current margins This means they would need to grow their revenue by 817% just to justify their current share price. It seems safe to assume a stock with an 817% revenue growth already priced in is a perilous place to have any capital invested.
In summary, I predict the next 12 to 18 months will see a pretty steep decline in the average share prices of these five companies. But the next time you get offered shares in an IPO selling 3D-manufactured cannabis-infused baby powder you can be sure that for the short term at least you are in for a ride.
